Cardiol Therapeutics Q3 2026: What the Miss Really Means
As seen on the 24/7 Wall St. homepage on November 12, 2026.
The wider loss is almost entirely non-cash: a $3.85 million warrant revaluation hit that grew because the stock went up. What matters is the $33.2 million cash balance as of November 12, enough to fund operations into Q1 2028 and carry the Phase III MAVERIC pericarditis trial to topline results in mid-2027.
Continue ReadingShow less
Cardiol Therapeutics reported a Q3 2026 loss per share of $0.08, missing expectations. The number that drove the wider loss is a $3.85 million non-cash charge from revaluing a warrant derivative liability, an accounting adjustment that grew precisely because the stock price rose during the quarter.
Strip out that warrant revaluation and the underlying operating picture looks considerably more controlled. Research and development spending fell to $3.87 million as costs on the completed Phase II ARCHER myocarditis study wound down sharply. The company carries no revenue, consistent with its pre-commercial status, so burn rate management and cash runway are the metrics that matter most to investors at this stage.
Cash as of November 12, 2026, including proceeds from the new US$75 million at-the-market program with Jefferies, stood at $33.2 million. Management projects that balance funds operations and corporate milestones into Q1 2028, well past the mid-2027 date when topline results from the Phase III MAVERIC trial are expected.
Sponsored
MAVERIC is the central catalyst for the stock. The pivotal trial of CardiolRx in recurrent pericarditis hit its original 110-patient enrollment target in September 2026, and the Steering Committee then recommended expanding to up to 150 patients. That expansion pushed the full enrollment deadline to Q4 2026 and shifted topline readout to mid-2027, with an estimated $6.8 million in remaining trial costs. CardiolRx holds FDA Orphan Drug Designation for the indication, and the company has said successful results would support a New Drug Application.
The reported loss per share has narrowed substantially from the $0.10 range seen through much of 2025, with Q1 and Q2 2026 coming in well below consensus before the Q3 warrant charge pulled the figure back up. That pattern underscores how much the reported GAAP number can swing on non-cash items, making the cash balance and trial timeline the more reliable signals for where this company stands.
Mentioned: CRDL